1 / 67

Genetics of the Hemoglobinopathies & Newborn Screening for the Hemoglobinopathies

Genetics of the Hemoglobinopathies & Newborn Screening for the Hemoglobinopathies. 张咸宁 zhangxianning@zju.edu.cn Tel: 13105819271; 88208367 Office: A705, Research Building 2013/03. Required Reading. Thompson &Thompson Genetics in Medicine, 7 th Ed (双语版, 2009 ) ● Pages 237-257;

citizen
Download Presentation

Genetics of the Hemoglobinopathies & Newborn Screening for the Hemoglobinopathies

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Genetics of the Hemoglobinopathies & Newborn Screening for the Hemoglobinopathies 张咸宁 zhangxianning@zju.edu.cn Tel:13105819271; 88208367 Office: A705, Research Building 2013/03

  2. Required Reading Thompson &Thompson Genetics in Medicine, 7th Ed (双语版,2009) ● Pages 237-257; ● Clinical Case Studies: 37. Sickle Cell Disease 39. Thalassemia

  3. Part I. Genetics of the Hemoglobinopathies

  4. Learning Objectives • To review the normal structure-function relationships of hemoglobin and expression of globin genes • To examine the hemoglobinopathies as disorders of hemoglobin structure, or α- or β-globin gene expression • To explore the influences of compound heterozygosity and modifier genes on hemoglobinopathy phenotypes

  5. Molecular Disease A disease in which there is an abnormality in or a deficiency of a particular molecule, such as hemoglobin in sickle cell anemia.

  6. The Effect of Mutation on Pr Function • Loss of Pr function (the great majority): is seen in (1)recessive diseases;(2)diseases involving haploinsufficiency, in which 50% of the gene product is insufficient for normal function; and (3)dominant negative mutations, in which the abnormal protein product interferes with the normal protein product.

  7. The Effect of Mutation on Pr Function 2. Gain of function: are sometimes seen in dominant diseases. 3. Novel property(infrequent) 4. The expression of a gene at the wrong time (Heterochronic expression), or in the wrong place (Ectopic expression), or both. (uncommon, except in cancer)

  8. Hemoglobinopathies • Disorders of the human hemoglobins • Most common single gene disorders in the world • WHO: 5% of the world’s population are carriers for clinically significant hemoglobinopatihies • Well understood at biochemical and molecular levels

  9. HbA: α2β2 • Globular tetramer • MW 64.5 kD • α-Chain • Maps to chromosome 16 • Polypeptide length of 141 amino acids • β-Chain • Maps to chromosome 11 • Polypeptide length of 146 amino acids

  10. Normal Human Hbs • Six including HbA • Each has a tetrameric structure • Two α or α-like genes • Clustered on chromosome 16 • Two non-α genes • Clustered on chromosome 11

  11. Globin Tertiary Structure • Eight helices: A-H • Two globins highly conserved • Phe 42: wedges heme porphyrin ring into heme pocket • Mut: Hb Hammersmith • His 92: covalently links heme iron • Mut: Hb Hyde Park

  12. Gene cluster: A group of adjacent genes that are identical or related. Pseudogene: DNA sequence homologous with a known gene but is non-functional.

  13. Developmental Expression of Globin Genes and Globin Switching

  14. Globin Gene Developmental Expression and Globin Switching • Classical example of ordered regulation of developmental gene expression • Genes in each cluster arranged in • Same transcriptional orientation • Same sequential order as developmental expression • Equimolar production of α-like and β-like globin chains

  15. Human Hemoglobins: Prenatal • Embryonic • 22 • Fetal: HbF • α22 • Predominates 5 wks gestation to birth • ~70% of total Hb at birth • <1% of total Hb in adulthood

  16. Human Hemoglobins: Postnatal • Adult: HbA • 22 •  chain synthesis increases through birth • Nearly all Hb is HbA by 3 mos of age • HbA2 • 22 • ≤2% of adult Hb • Consequence of continuing synthesis of  chains

  17. Clinic Disease: Influences of Gene Dosage and Developmental Expression • Dosage • 4 - vs. 2 -globin alleles per diploid genome • Therefore, mutations required in 4 -globin alleles compared with 2 -globin alleles for same 100% loss of function • Ontogeny •  expressed before vs.  expressed after birth • Therefore, -chain mutations have prenatal consequences, but -chain mutations are not evidenced even in the immediate postnatal period

  18. The normal human Hbs at different stages of development

  19. Genetic disorders of Hb 1. Structural variants: alter the globin polypeptide without affecting its rate of synthesis. 2. Thalassemias: reduced rate of production of one or more globin chains. 3. Hereditary persistence of fetal hemoglobin (HPFH) : a group of clinically benign conditions, impairing the perinatal switch from γ- toβ-globin synthesis.

  20. There are >400 structural variants of normal Hb. The 4 most common structural variants are: • Hb S(Sickle cell anemia): β chain: Glu6Val • Hb C: β chain: Glu6Lys • Hb E: β chain: Glu26Lys • Hb M(Methemoglobin):An oxidizing form of Hb containing ferric iron that is produced by the action of oxidizing poisons. Non-functional.

  21. HbS is the first variant to be discovered (1949). Its main reservoir is Central Africa where the carrier rate approximates 20%. (Heterozygous advantage) Approximately 8% of African-Americans will carry one sickle gene.

  22. Heterozygote Advantage • Mutant allele has a high frequency despite reduced fitness in affected individuals. • Heterozygote has increased fitness over both homozygous genotypes e.g. Sickle cell anemia.

  23. Thalassemia: An imbalance of globin-chain synthesis • Hemoglobin synthesis characterized by the absence or reduced amount of one or more of the globin chains of hemoglobin. • α-thalassemia • β-thalassemia

  24. Varius forms of α-Thalassemia

  25. Hb Bart’s (hydrops fetalis)

  26. β-thalassemia:underproduction of the β-chain. ●β-thal trait (β+/ β orβ0 /β) : .asymptomatic (β+:reduced;β0:absent) ●β-thal intermedia (β+/ β+ ): . moderate anemia ●β-thal major (β0 /β0 orβ+/β0 or β+/ β+ ) : . severe anemia during the first two years of life . hepatosplenomegaly . growth failure . jaundice . thalassemic facies

  27. Thalassemias can arise in the following ways: • One or more of the genes coding for hemoglobin chains is deleted. • 2. A nonsense mutation that produces a shortened chain. • 3. A frameshift mutation that produces a nonfunctional chain. • 4. A mutation may have occurred outside the codingregions.

  28. β-globin gene andβ-thalassemia

  29. Thalassemias: Pathological Effect of Globin Chain Excess • Thalassemia • Spleen from -thal homozygote • Excess -chains form a Heinz body inclusion (seen also in -thal) • Inclusions • Removed by reticulo-endothelial cells • Membranes damaged • RBCs destroyed

  30. Phenotypic Consequences of Allelic Interactions and Modifier Genes

  31. Allelic Interactions • Relatively high frequency of alleles in populations • Example • thalS • If 0 then may be like sickle cell disease • If + then may be much milder

  32. Modifier Genes: Locus Interactions • These would involve mutations in the  and  loci • Example • -thal homozygotes who also inherit an -thal allele may have less severe -thalassemia, due to less imbalance or reduced excess -globin chains

  33. Part II. Newborn Screening for the Hemoglobinopathies

  34. Learning Objectives • To review the evolving principles of newborn screening • To examine newborn screening (NBS) for the hemoglobinopathies • To understand the appropriate response to a positive hemoglobinopathy NBS • To appreciate the role of clinical follow-up for the hemoglobinopathies

  35. Population-Based Screening

  36. Genomic Medicine • Principles • Predictive • Preventive • Personalized • Change from current paradigm with emphasis on acute intervention • Will rely on strategies from preventive medicine and public health

  37. Genetic Screening • Population-based approach to identify individuals with certain genotypes known to be • Associated with a genetic disease, or • Predisposition to a genetic disease • Disorder targeted may affect • Individuals being screened, or • Their descendents

  38. Objective of Population Screening • To examine all members of the population designated for screening • Carried out without regard for family history • Should not be confused with testing for affected individuals or carriers within families ascertained because of a positive family history

  39. Genetic Screening • Important public health activity • Will have increasingly significant role with availability of more and better screening tests for • Genetic diseases • Diseases with an identifiable genetic component • Critical strategic hurdle for implementation • Venue in which to capture 100% of target population

  40. Principles of Newborn Screening (NBS)

  41. NBS • Public health governmental programs • Population screening for all neonates • Intervention • Prevents or at least ameliorates consequences of targeted disease • Cost-effective • Controversial • Not simply a test, but a system

  42. Criteria for Effective NBS Programs • Treatment is available. • Early institution of treatment before symptoms become manifest has been shown to reduce or eliminate the severity of the illness. • Routine observation and physical examination will not reveal the disorder in the newborn – a test is required.

More Related